ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression
NCT06408246
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Depression
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Stanford University
- Last updated on ClinicalTrials.gov
- March 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Stanford Psychiatry and Behavioral Sciences Department · Palo Alto, CA
Illinois · 1
- University of Illinois at Chicago · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.